



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

# Reverse transcription loop-mediated isothermal amplification (RT-LAMP) for point-of-care detection of SARS-CoV-2: a clinical study to evaluate agreement with RT-qPCR



Mary Natoli\*, Kathryn Kundrod\*, Megan Chang, Chelsey Smith, Sai Paul, Karen Eldin, Keyur Patel, Ellen Baker, Kathleen Schmeler, Rebecca Richards-Kortum

## Abstract

**Background** The global COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted the need for rapid, accurate, and accessible diagnostics to enable timely treatment and outbreak control. However, current diagnostic tests based on RT-qPCR are insufficient to meet the global testing demand because of their high cost and complexity and supply chain shortages. Reverse transcription loop-mediated isothermal amplification (RT-LAMP) is a promising alternative to RT-qPCR because of its sensitivity, speed, and robustness to sample inhibitors. Here, we describe the development and optimisation of a sample-to-answer workflow, including a simple lysis and inactivation protocol that provides results in <1h, using inexpensive and readily available reagents. Further, we assess the sensitivity and specificity of the developed RT-LAMP assay against a RT-qPCR.

**Methods** We collected samples from asymptomatic healthcare workers at The University of Texas MD Anderson Cancer Center and inpatients at Lyndon B Johnson Hospital in Houston, TX, USA. Nasopharyngeal swabs were collected by medical providers and were placed directly into 300  $\mu$ L of an optimised lysis buffer. Samples were heat inactivated at 95°C for 5 mins before direct amplification in a RT-LAMP assay using previously published primer sets. Heating and real-time monitoring was performed using a Bio-Rad CFX96 thermocycler and an Axxin T8-ISO, a benchtop fluorimeter designed for point-of-care settings. We compared results from the RT-LAMP test with standard-of-care RT-qPCR results on paired nasopharyngeal swabs collected into Universal Viral Transport Media.

**Findings** The developed RT-LAMP assay demonstrated a limit of detection of 4–5 virions/ $\mu$ L. The test requires a swab, two tubes, prepared lysis buffer, a heat block, pipettes, RT-LAMP reagents, and the real-time fluorimeter. Samples were collected between April 14, 2020 and Aug 12, 2020, and results from 74 enrolled participants were analysed in the optimised workflow. Thirty nine participants tested positive for SARS-CoV-2 and 35 participants tested negative in the hospital-administered RT-qPCR test. All 74 nasopharyngeal swab eluates were tested with our assay on the Bio-Rad CFX96; 72 nasopharyngeal swab eluates were also tested on the Axxin T8-ISO. The developed assay showed sensitivity of 92.31% and 91.89% when tested on the CFX96 and T8, respectively, and specificity of 91.43% and 97.89%, respectively.

**Interpretation** RT-LAMP could be used for SARS-CoV-2 testing and overcomes the challenges of adapting an assay to a point-of-care instrument. Further, the reduced instrumentation cost and complexity, along with the simple workflow, highlight the potential for implementation of RT-LAMP for SARS-CoV-2 testing in resource-limited settings.

**Funding** USAID, IAVI, and Rice University.

**Copyright** © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

### Declaration of interests

We declare no competing interests.

Published Online  
March 11, 2021

\*These authors contributed equally to this work

Rice University, Department of Bioengineering (M Natoli PhD, K Kundrod PhD, M Chang BA, C Smith BE, S Paul BS, R Richards-Kortum PhD) Houston, TX, USA; McGovern Medical School, The University of Texas Health Science Center, Department of Pathology and Laboratory Medicine, Houston, TX (K Eldin MD); University of Texas MD Anderson Cancer Center, Department of Hematopathology (K Patel MD) and Department of Gynecologic Oncology and Reproductive Medicine (E Baker MD, K Schmeler MD), Houston, TX, USA

Correspondence to:  
Dr Rebecca Richards-Kortum,  
6100 Main Street, MS-142  
Houston, TX 77005, USA  
rkortum@rice.edu